What’s the Latest Research in Lynch Syndrome?  

Lynch syndrome is an inherited condition that increases an individual’s risk for certain types of cancer. It’s caused by a mutation in any of five specific genes: MLH1, MSH2, MSH6, PMS2, and EPCAM.   People born with a mutation in one or more of these genes have a significantly increased risk of developing colorectal or uterine cancer and a somewhat … Read more

Bispecific Antibody Therapy for Lymphoma: What You Need to Know   

Bispecific antibody therapies are a type of immunotherapy for patients with B-cell non-Hodgkin lymphoma. These therapies provide a valuable new option for patients.  There are many standard therapies that are monoclonal antibodies. These therapies treat cancer by binding to a marker on cancer cells and rallying the immune system to destroy them.  Bispecific antibodies are … Read more

BCL2 Inhibitors: What’s the Latest Research?

BCL2 inhibitors are drugs that prompt cancer cells to die by altering the interactions among key proteins within the cells. They were clinically developed, in large part, by researchers at Dana-Farber and have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML) and chronic lymphocytic leukemia … Read more

What is Protein Degradation? 

Protein degradation is a natural process by which cells break down proteins that are damaged or no longer needed so they can be recycled or disposed of.  Scientists at Dana-Farber and elsewhere are harnessing this process to destroy specific proteins involved in cancer, an approach known as targeted protein degradation. In contrast to traditional targeted … Read more

Clinical Trials for Patients with Cancer 

Clinical trials are scientific studies in which new treatments — drugs, diagnostic procedures, and other therapies — are tested in people to find out if they are safe and effective. Nearly all cancer drugs in use today were tested in clinical trials.  If you have been diagnosed with cancer, the benefits of participating in a clinical … Read more

How Dana-Farber Investigators Seize Opportunities to Advance Medicine

Investigators who run investigator-initiated trials (IITs) have two essential qualities. One is curiosity, which keeps them alert, aware of discoveries, and able to make connections that lead to new treatment ideas.   The second is determination.   “The burden of responsibility for what is typically a many-year-long study falls on that one investigator,” says Ursula Matulonis, MD, … Read more

Can Less Treatment for Colorectal Cancer Yield the Same Results? 

Colon and rectal cancer combined are the fourth most commonly diagnosed cancers.  Eighty percent of patients are diagnosed at a stage of disease when treatment is given with curative-intent.  However, treatment can have both short- and long-term side effects that may impact quality of life.   To address these concerns, investigators at Dana-Farber have led clinical … Read more

Could AI Help Doctors Predict Pancreatic Cancer? 

As a cancer imaging fellow at Dana-Farber, Michael Rosenthal, MD, PhD, spent about two years working on a radiologist’s version of paint-by-number. Together with his colleagues, he annotated 687 computed tomography (CT) scans, manually differentiating skeletal muscle from fat tissue by labelling them with different colors.   The work was part of a 2018 project to … Read more

Bridging the Gap Between Medical AI Research and Real-World Clinical Impact 

Artificial Intelligence (AI) has tremendous potential to advance healthcare and improve the lives of everyone. But successful clinical translation requires evaluating the performance of AI models on large and diverse real-world datasets. MLCommons, an open global engineering consortium dedicated to making machine learning better for everyone, announced on July 17, 2023, a major milestone toward … Read more

Living Systematic Review Guides Prostate Cancer Treatment Options

As science and clinical medicine advance, oncologists increasingly face the challenge of information overload. It can be hard for oncologists, especially those in community practices who cover many cancers, to keep up with the influx of new therapies, biomarkers, and clinical trial results. The go-to solution has been the systematic review. Researchers team up to … Read more